HOME >> MEDICINE >> NEWS
Brief, high-dose steroid treatment offers extended relief to giant cell arteritis patients

ATLANTA -- A new study offers both hope and a practical treatment option for patients with giant cell arteritis (GCA). Researchers from Emory University and the Mayo Clinic have found that by treating newly diagnosed GCA patients with just three days of a high-dose intravenous steroid, patients relapsed less in the following year and were able to significantly taper off usage of an oral steroid. The study is published in the October issue of the journal Arthritis & Rheumatism.

Giant cell arteritis is characterized by inflammation of arteries, primarily in the head, and affects 20 out of every 100,000 people. GCA inflammation may lead to swelling and headaches, or, as it progresses, vision loss, strokes and aortic aneurysms. While past research has shown a genetic link to the disease, which primarily affects Caucasian women over the age of 50, there is no known cause or cure.

For the last 40 years, physicians have been able to treat and reverse some symptoms of GCA by prescribing prednisone, to be taken daily over a year or more. "Patients improve promptly and reliably, within days of when we treat them," says Cornelia M. Weyand, MD, PhD, co-director of the Kathleen B. and Mason I. Lowance Center for Human Immunology at Emory University and an author of the paper. "The problem is that patients have to take prednisone for a long time and in high doses, and they are at risk of developing side effects." Common side effects include hypertension, diabetes and osteoporosis.

While scientists have attempted to develop new drugs that would be more effective and have fewer side effects, their results have been unsuccessful. "We and others tried to look into other types of treatments that could help with this disease," says Jrg Goronzy, MD, PhD, senior author of the paper, and co-director of the Lowance Center.

"Even the modern and effective immunosuppressants do not improve the situation with these patients," says Dr. Weyan
'"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University Health Sciences Center
2-Oct-2006


Page: 1 2

Related medicine news :

1. Study examines characteristics of female high school students who report steroid use
2. Female teen steroid use not limited to athletes
3. Bronchial thermoplasty may allow severe asthma patients to wean off oral corticosteroids
4. Inhaled steroids may not be enough for some children with asthma
5. Nonsteroidal anti-inflammatory drugs use associated with higher gastrointestinal complications
6. Short-term topical corticosteroid use may offer relief for patients with acute form of psoriasis
7. Pre-clinical study suggests how steroid can reverse post-traumatic stress
8. Inhaled corticosteroids reduce death in patients with COPD
9. Non-steroidal anti-inflammatory drugs (NSAIDs) and congenital anomalies
10. National trial gives unprecedented support for steroid withdrawal in kidney transplants
11. New study adds weight to argument for steroid injections in patients with hip osteoarthritis

Post Your Comments:
(Date:7/22/2014)... A Florida woman has filed a ... the death of her husband was the result of ... Liebhard LLP reports. According to her complaint, which was ... Southern District of Florida on June 23rd, the decedent ... subdural hemorrhage the following June. Despite emergency treatment, his ...
(Date:7/22/2014)... 22, 2014) The American Society of Hematology ... University of California Los Angeles with the 2014 ... iron homeostasis, including the discovery of the iron-regulatory hormone ... This award, named after the Nobel Prize Laureate and ... research achievements in hematology that have represented a paradigm ...
(Date:7/22/2014)... you,re a member of the Clean Plate Club you ... you,re not alone! A new Cornell University study shows ... she puts on his or her plate. "If ... stomach," says Brian Wansink Ph.D., author of the forthcoming book, ... Cornell Food and Brand Lab. , Wansink and co-author Katherine ...
(Date:7/22/2014)... 2014) -- The American Society of Hematology (ASH) will ... Coulter Award for Lifetime Achievement in Hematology, to Kanti ... Jewish (LIJ) School of Medicine for his 50-year career ... and mentoring, and exceptional patient care. , The ... is bestowed on an individual who has been a ...
(Date:7/22/2014)... July 22, 2014 SIMpalm, ... updated payment app for Forte Payment System. Forte Mobile ... ACH payments on iPhone, iPod and iPad. The ... been recently updated by SIMpalm. This update was for ... currently supported on iOS 4.3 and is available to ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 3Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3
(Date:7/22/2014)... 22, 2014 BiologicTx ® today announced ... 3-way Kidney Paired Donation transplant exchange utilizing BiologicTx,s proprietary ... July 9 at the Miami Transplant Institute, located at ... Kidney Paired Donation (KPD) is ... for kidney transplant with one another due to incompatible ...
(Date:7/22/2014)...  A central New York ... Total Artificial Heart implant is home, discharged from ... Freedom® portable driver to wait for a matching ... from a Syracuse architectural hardware company, suffered from ... medications, an implantable defibrillator and a pacemaker. ...
(Date:7/22/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today ... patients in its ongoing Phase 2 trial (Study 202) ... revised clinical protocol agreed to with the FDA in ... proprietary recombinant human hyaluronidase under development for the systemic ... "Our diligent effort to rapidly re-initiate patient enrollment and ...
Breaking Medicine Technology:BiologicTx Paired Donation Aids In Successful Kidney Transplants 2BiologicTx Paired Donation Aids In Successful Kidney Transplants 3'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 2'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 3Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3
Cached News: